Breaking News Bar

Business News and Information

Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oxford Immunotec Global PLC (NASDAQ:OXFD), Ascena Retail Group, Inc. (NASDAQ:ASNA), Groupon, Inc. (NASDAQ:GRPN), Epizyme, Inc. (NASDAQ:EPZM), Regulus Therapeutics Inc. (NASDAQ:RGLS), and B Communications Ltd. (NASDAQ:BCOM), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

OXFD DOWNLOAD: http://Fundamental-Markets.com/register/?so=OXFD
ASNA DOWNLOAD: http://Fundamental-Markets.com/register/?so=ASNA
GRPN DOWNLOAD: http://Fundamental-Markets.com/register/?so=GRPN
EPZM DOWNLOAD: http://Fundamental-Markets.com/register/?so=EPZM
RGLS DOWNLOAD: http://Fundamental-Markets.com/register/?so=RGLS
BCOM DOWNLOAD: http://Fundamental-Markets.com/register/?so=BCOM

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Oxford Immunotec Global PLC (NASDAQ:OXFD), Ascena Retail Group, Inc. (NASDAQ:ASNA), Groupon, Inc. (NASDAQ:GRPN), Epizyme, Inc. (NASDAQ:EPZM), Regulus Therapeutics Inc. (NASDAQ:RGLS), and B Communications Ltd. (NASDAQ:BCOM) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 15th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

OXFORD IMMUNOTEC GLOBAL PLC (OXFD) REPORT OVERVIEW

Oxford Immunotec Global's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Oxford Immunotec Global reported revenue of $29.32MM vs $26.12MM (up 12.24%) and analysts estimated basic earnings per share -$0.25 vs -$0.74. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Oxford Immunotec Global reported revenue of $103.08MM vs $86.08MM (up 19.75%) and analysts estimated basic earnings per share -$1.38 vs -$1.00. Analysts expect earnings to be released on October 30th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.24. The estimated EPS forecast for the next fiscal year is -$0.65 and is expected to report on February 26th, 2019.

To read the full Oxford Immunotec Global PLC (OXFD) report, download it here: http://Fundamental-Markets.com/register/?so=OXFD

-----------------------------------------

ASCENA RETAIL GROUP, INC. (ASNA) REPORT OVERVIEW

Ascena Retail Group's Recent Financial Performance

For the three months ended July 31st, 2018 vs July 31st, 2017, Ascena Retail Group reported revenue of $1,766.30MM vs $1,658.10MM (up 6.53%) and analysts estimated basic earnings per share $0.17 vs -$0.08. For the twelve months ended July 31st, 2018 vs July 31st, 2017, Ascena Retail Group reported revenue of $6,578.30MM vs $6,649.80MM (down 1.08%) and analysts estimated basic earnings per share -$0.20 vs -$5.48. Analysts expect earnings to be released on December 3rd, 2018. The report will be for the fiscal period ending October 31st, 2018. Reported EPS for the same quarter last year was $0.11. The estimated EPS forecast for the next fiscal year is $0.14 and is expected to report on September 23rd, 2019.

To read the full Ascena Retail Group, Inc. (ASNA) report, download it here: http://Fundamental-Markets.com/register/?so=ASNA

-----------------------------------------

GROUPON, INC. (GRPN) REPORT OVERVIEW

Groupon's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Groupon reported revenue of $617.40MM vs $662.62MM (down 6.82%) and analysts estimated basic earnings per share -$0.17 vs -$0.02. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Groupon reported revenue of $2,843.88MM vs $3,013.62MM (down 5.63%) and analysts estimated basic earnings per share $0.03 vs -$0.34. Analysts expect earnings to be released on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was -$0.01. The estimated EPS forecast for the next fiscal year is $0.12 and is expected to report on February 13th, 2019.

To read the full Groupon, Inc. (GRPN) report, download it here: http://Fundamental-Markets.com/register/?so=GRPN

-----------------------------------------

EPIZYME, INC. (EPZM) REPORT OVERVIEW

Epizyme's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Epizyme reported revenue of $12.00MM vs $10.00MM (up 20.00%) and basic earnings per share -$0.42 vs -$0.48. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Epizyme reported revenue of $10.00MM vs $8.01MM (up 24.89%) and analysts estimated basic earnings per share -$2.18 vs -$1.93. Analysts expect earnings to be released on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.63. The estimated EPS forecast for the next fiscal year is -$2.15 and is expected to report on March 12th, 2019.

To read the full Epizyme, Inc. (EPZM) report, download it here: http://Fundamental-Markets.com/register/?so=EPZM

-----------------------------------------

REGULUS THERAPEUTICS INC. (RGLS) REPORT OVERVIEW

Regulus Therapeutics' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Regulus Therapeutics reported revenue of $0.02MM vs $0.02MM (unchanged) and analysts estimated basic earnings per share -$1.57 vs -$4.94. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Regulus Therapeutics reported revenue of $0.07MM vs $1.19MM (down 93.97%) and analysts estimated basic earnings per share -$11.57 vs -$18.67. Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$2.16. The estimated EPS forecast for the next fiscal year is -$3.59 and is expected to report on March 6th, 2019.

To read the full Regulus Therapeutics Inc. (RGLS) report, download it here: http://Fundamental-Markets.com/register/?so=RGLS

-----------------------------------------

B COMMUNICATIONS LTD. (BCOM) REPORT OVERVIEW

B Communications' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2016, B Communications reported revenue of $639.00MM vs $653.00MM (down 2.14%) and analysts estimated basic earnings per share -$2.89 vs $0.35. For the twelve months ended December 31st, 2017 vs December 31st, 2016, B Communications reported revenue of $2,823.00MM vs $2,623.00MM (up 7.62%) and analysts estimated basic earnings per share $0.76 vs -$2.06. Analysts expect earnings to be released on November 29th, 2018. The report will be for the fiscal period ending September 30th, 2018.

To read the full B Communications Ltd. (BCOM) report, download it here: http://Fundamental-Markets.com/register/?so=BCOM

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear